Palivizumab Antibody | AbD23967

//www.bio-rad-antibodies.com/palivizumab-antibody-abd23967-hca261.html?RenderPageSpecific=1
Palivizumab Antibody | AbD23967 gallery image 1

Human anti palivizumab specificity ELISA
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using human anti palivizumab (clone AbD23967) at a concentration of 2 μg/ml followed by an HRP labeled anti-DYKDDDDK tag antibody in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate

Enlarge
Palivizumab Antibody | AbD23967 gallery image 2

Human anti palivizumab specificity titration ELISA
A microtiter plate was coated over night with palivizumab, human IgG1/kappa, human IgG1/lambda, natalizumab, trastuzumab or tocilizumab at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using human anti palivizumab (clone AbD23967) titrated to the given concentrations in PBST, followed by an HRP labeled anti-His tag antibody in HISPEC diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data for binding to palivizumab is presented as the mean of three measurements

Enlarge
Palivizumab Antibody | AbD23967 gallery image 3

Palivizumab bridging ELISA for pharmacokinetic (PK) assay development
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Palivizumab Antibody | AbD23967 gallery image 4

Palivizumab bridging ELISA for pharmacokinetic (PK) assay development
A microtiter plate was coated over night with human anti palivizumab (clone AbD23967) at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of palivizumab. Detection was performed using HRP-conjugated human anti palivizumab (clone AbD23967_hIgG1) at a concentration of 2 μg/ml in HISPEC assay diluent (BUF049A) and QuantaBlu™ fluorogenic peroxidase substrate. Data is presented as the mean of three measurements. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
  • Palivizumab Antibody | AbD23967 thumbnail image 1
  • Palivizumab Antibody | AbD23967 thumbnail image 2
  • Palivizumab Antibody | AbD23967 thumbnail image 3
  • Palivizumab Antibody | AbD23967 thumbnail image 4
  • Human anti Palivizumab
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-palivizumab antibody is a recombinant, neutralizing, anti-idiotypic antibody in monovalent Fab format; it is ideal for bioanalytical assays to measure levels of palivizumab and biosimilars. It is suitable as capture and detection antibody in a PK bridging ELISA format.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD23967
    • Isotype
      HuCAL Fab monovalent
    1 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA261Edatasheet pdfdatasheet pdf0.1 mg
      HCA261
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti Palivizumab, clone AbD23967, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.

        Our anti palivizumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in monovalent Fab format, is recommended as the capture antibody, paired with the antibody in full immunoglobulin (Ig) format, clone AbD23967_hIgG1 (HCA262), as the detection antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

        Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.

        View a summary of all anti-palivizumab antibodies
      • Intended Use
      • Product Form
        A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.
      • Reconstitution
      • Preparation
        Metal chelate affinity chromatography
      • Preservative Stabilisers
        0.01% Thiomersal
      • Immunogen
        Palivizumab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD = 1.5 nM by real time, label free molecular interaction analysis on immobilized palivizumab.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
      • Shelf Life
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Synagis® is a registered trademark of the AstraZeneca group of companies.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • ELISA
        This product may be used in direct or indirect ELISA and in a PK bridging ELISA as a capture antibody together with the same antibody or HCA262P as the detection reagent.
        Protocol: PK bridging ELISA to measure free drug
      • Immunohistology
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Western Blotting
      • Instructions For Use

      Additional Palivizumab Antibody Formats

      Formats Clone Applications Sizes available
      Palivizumab Antibody : Purified AbD23967 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        DescriptionProduct CodePack SizeApplicationsList PriceQuantity
        Rat anti DYKDDDDK Tag:HRPMCA4764P0.1 mgE, P, WB
        MCA4764P
        Mouse anti Penta Histidine Tag:HRPMCA5995P125 µlE, WB
        MCA5995P

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Human anti PalivizumabHCA2620.1 mgE
            HCA262
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...